Establishment of a novel whole animal HTS technology platform for melioidosis drug discovery

Combinatorial Chemistry and High Throughput Screening

Volumn 17, Issue 9, 2014, Pages 790-803

  Lakshmanan, Umayal ^a   Yap, Amelia ^a   Fulwood, Justina ^a   Yichun, Li ^b   Hoon, Sim Siew ^b   Lim, Jolander ^a   Ting, Audrey ^a   Sem, Xiao Hui ^c   Kreisberg, Jason F ^c   Tan, Patrick ^c   Tan, Gladys ^b   Flotow, Horst ^a  

^a Agency for Science   (Singapore)

^b DSO NATIONAL LABORATORIES   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

C. elegans; HTS; Melioidosis drug discovery; Whole animal screening

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; CLINAFLOXACIN; COTRIMOXAZOLE; DEMECLOCYCLINE; DOXYCYCLINE; ENROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; ANTIINFECTIVE AGENT; MOLECULAR LIBRARY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; BIOTECHNOLOGY; BURKHOLDERIA THAILANDENSIS; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG DESIGN; DRUG DETERMINATION; DRUG SCREENING; FLUORESCENCE; HIGH THROUGHPUT SCREENING; IC50; MELIOIDOSIS; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BURKHOLDERIA PSEUDOMALLEI; CHEMISTRY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; MICROBIOLOGY; PHARMACOLOGY;

ANIMALIA; BURKHOLDERIA PSEUDOMALLEI; BURKHOLDERIA THAILANDENSIS; CAENORHABDITIS ELEGANS; NEGIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; MELIOIDOSIS; SMALL MOLECULE LIBRARIES;

EID: 84929093309     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207317666141019195031     Document Type: Article

References (46)

1. Cheng, A. C.; Currie, B. J. Melioidosis: epidemiology, pathophysiology, and management. Clin. Microbiol. Rev., 2005, 18, 383-416.
2. Meumann, E. M.; Cheng, A. C.; Ward, L.; Currie, B. J. Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. Clin. Infect. Dis., 2012, 54, 362-369.
3. Wiersinga, W. J.; Currie, B. J.; Peacock, S. J. Melioidosis. N. Engl. J. Med., 2012, 367, 1035-1044.
4. Lipsitz, R.; Aurigemma, R.; Baccam, P.; Blaney, D. D.; Cheng, A. C.; Currie, B. J.; Dance, D.; Gee, J. E.; Larsen, J.; Limmathurotsakul, D.; Morrow, M. G.; Norton, R.; O'Mara, E.; Peacock, S. J.; Pesik, N.; Rogers, L. P.; Garges, S.; Schweizer, H. P.; Steinmetz, I.; Tan, G.; Tan, P.; Wiersinga, W. J.; Wuthiekanun, V.; Smith, T. L. Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010 - Emerging Infectious Disease journal - CDC http://www.expert-reviews.com/doi/abs/10.1586/14787210.4.3.445 (accessed Dec. 7, 2012).
5. Program, F. S. A. HHS AND USDA SELECT AGENTS AND TOXINS. http://www.selectagents.gov/resources/List-of-Select-Agents-and-Toxins-2012-12-4-English.pdf 2013, 1-1.
6. Estes, D. M.; Dow, S. W.; Schweizer, H. P.; Torres, A. G. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev. Anti. Infect. Ther., 2010, 8, 325-338.
7. Pagnarith, Y. Y.; Kumar, V. V.; Thaipadungpanit, J. J.; Wuthiekanun, V. V.; Amornchai, P. P.; Sin, L. L.; Day, N. P. N.; Peacock, S. J. S. Emergence of pediatric melioidosis in Siem Reap, Cambodia. Audio, Transactions of the IRE Professional Group on 2010, 82, 1106-1112.
8. Walsh, A. L.; Smith, M. D.; Wuthiekanun, V.; Suputtamongkol, Y.; Chaowagul, W.; Dance, D. A.; Angus, B.; White, N. J. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin. Infect. Dis., 1995, 21, 1498-1500.
9. Limmathurotsakul, D.; Peacock, S. J. Melioidosis: a clinical overview. Br. Med. Bull., 2011, 99, 125-139.
10. Chandni, R. Melioidosis: The Great Mimicker. apiindia.org
11. Yee, K. C.; Lee, M. K.; Chua, C. T.; Puthucheary, S. D. Melioidosis, the great mimicker: a report of 10 cases from Malaysia. J. Trop. Med. Hyg., 1988, 91, 249-254.
12. Wiersinga, W. J.; Currie, B. J.; Peacock, S. J. Melioidosis. N. Engl. J. Med., 2012, 367, 1035-1044.
13. Chantratita, N. N.; Rholl, D. A. D.; Sim, B. B.; Wuthiekanun, V. V.; Limmathurotsakul, D. D.; Amornchai, P. P.; Thanwisai, A. A.; Chua, H. H. H.; Ooi, W. F. W.; Holden, M. T. G. M.; Day, N. P. N.; Tan, P. P.; Schweizer, H. P. H.; Peacock, S. J. S. Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei. Proc. Natl. Acad Sci. U S A, 2011, 108, 17165-17170.
14. Thibault, F. M. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J. Antimicrob. Chemother., 2004, 54, 1134-1138.
15. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6, 29-40.
16. Sifri, C. D.; Begun, J.; Ausubel, F. M. The worm has turned - microbial virulence modeled in Caenorhabditis elegans. Trends Microbiol., 2005, 13, 119-127.
17. Smith, M. P.; Laws, T. R.; Atkins, T. P.; Oyston, P. C. F.; De Pomerai, D. I.; Titball, R. W. A liquid-based method for the assessment of bacterial pathogenicity using the nematode Caenorhabditis elegans. FEMS Microbiol. Lett., 2002, 210, 181-185.
18. Kaletta, T.; Hengartner, M. O. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov., 2006, 5, 387-398.
19. Ewbank, J. J.; Zugasti, O. C. elegans: model host and tool for antimicrobial drug discovery. Dis. Model. Mech., 2011, 4, 300-304.
20. Kaletta, T.; Butler, L.; Bogaert, T. Caenorhabditis elegans Functional Genomics in Drug Discovery: Expanding Paradigms. In: Model Organisms in Drug Discovery. Carroll, P. M., Fitzgerald, K., Eds.; John Wiley & Sons Ltd.: Chichester, UK, 2005, pp. 41-79.
21. Artal-Sanz, M.; De Jong, L.; Tavernarakis, N. Caenorhabditis elegans: A versatile platform for drug discovery. Biotechnol. J. 2006, 1, 1405-1418.
22. Zhou, Y.-M.; Shao, L.; Li, J.-A.; Han, L.-Z.; Cai, W.-J.; Zhu, C.-B.; Chen, D.-J. An efficient and novel screening model for assessing the bioactivity of extracts against multidrug-resistant Pseudomonas aeruginosa using Caenorhabditis elegans. Biosci. Biotechnol. Biochem., 2011, 75, 1746-1751.
23. Gosai, S. J.; Kwak, J. H.; Luke, C. J.; Long, O. S.; King, D. E.; Kovatch, K. J.; Johnston, P. A.; Shun, T. Y.; Lazo, J. S.; Perlmutter, D. H.; Silverman, G. A.; Pak, S. C. Automated highcontent live animal drug screening using c. elegans expressing the aggregation prone serpin α1-antitrypsin Z. PLoS ONE, 2010, 5, e15460.
24. Garvis, S.; Munder, A.; Ball, G.; De Bentzmann, S.; Wiehlmann, L.; Ewbank, J. J.; Tummler, B.; Filloux, A. Caenorhabditis elegans Semi-Automated Liquid Screen Reveals a Specialized Role for the Chemotaxis Gene cheB2 in Pseudomonas aeruginosa Virulence. PLoS Pathog., 2009, 5, e1000540.
25. Moy, T. I.; Conery, A. L.; Larkins-Ford, J.; Wu, G.; Mazitschek, R.; Casadei, G.; Lewis, K.; Carpenter, A. E.; Ausubel, F. M. High throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem. Biol., 2009, 4, 527-533.
26. Burns, A. R.; Kwok, T. C. Y.; Howard, A.; Houston, E.; Johanson, K.; Chan, A.; Cutler, S. R.; McCourt, P.; Roy, P. J. High throughput screening of small molecules for bioactivity and target identification in Caenorhabditis elegans. Nat. Protoc., 2006, 1, 1906-1914.
27. Gill, M. S.; Olsen, A.; Sampayo, J. N.; Lithgow, G. J. An automated high throughput assay for survival of the nematode Caenorhabditis elegans. Free Radic. Biol. Med., 2003, 35, 558-565.
28. Pulak, R. Techniques for analysis, sorting, and dispensing of C. elegans on the COPAS flow-sorting system. Methods Mol. Biol., 2006, 351, 275-286.
29. Stiernagle, T. Maintenance of C. elegans. WormBook 2006, 1-11.
30. Kanthawong, S.; Nazmi, K.; Wongratanacheewin, S.; Bolscher, J. G. M.; Wuthiekanun, V.; Taweechaisupapong, S. In vitro susceptibility of Burkholderia pseudomallei to antimicrobial peptides. International Journal of Antimicrobial Agents 2009, 34, 309-314.
31. O'Rourke, E. J.; Conery, A. L.; Moy, T. I. Whole-animal high throughput screens: the C. elegans model. Methods Mol. Biol., 2009, 486, 57-75.
32. Thongdee, M.; Gallagher, L. A.; Schell, M.; Dharakul, T.; Songsivilai, S.; Manoil, C. Targeted mutagenesis of Burkholderia thailandensis and Burkholderia pseudomallei through natural transformation of pcr fragments. Appl. Environ. Microbiol., 2008, 74, 2985-2989.
33. Ewbank, J. J. Tackling both sides of the host-pathogen equation with Caenorhabditis elegans. Microbes Infect., 2002, 4, 247-256.
34. Peacock, S. J. Melioidosis. Curr. Opin. Infect. Dis., 2006, 19, 421-428.
35. Wiersinga, W. J.; De Vos, A. F.; De Beer, R.; Wieland, C. W.; Roelofs, J. J. T. H.; Woods, D. E.; Van Der Poll, T. Inflammation patterns induced by different Burkholderia species in mice. Cell Microbiol., 2008, 10, 81-87.
36. Rainbow, L.; Hart, C. A.; Winstanley, C. Distribution of type III secretion gene clusters in Burkholderia pseudomallei, B. thailandensis and B. mallei. J. Med. Microbiol., 2002, 51, 374-384.
37. Johnson, P. D. R.; Irving, L. B.; Turnidge, J. D. 3: Communityacquired pneumonia. Med. J. Aust., 2002, 176, 341-347.
38. Moellering, R. C. The Emergence of Bacterial Resistance to Antibiotics: Achieving Optimum Outcomes with Clinafloxacin; a Seminar-in-print; Adis Internat., 1998.
39. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudmonas aeruginosa on length of hospital stay. Infect. Control. Hosp. Epidemiol., 2002, 23, 106-108.
40. Leung, C. K.; Wang, Y.; Malany, S.; Deonarine, A.; Nguyen, K.; Vasile, S.; Choe, K. P. An ultrahigh throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans. PLoS ONE, 2013, 8, e62166.
41. Livermore, D. M.; on behalf of the British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development; Blaser, M.; Carrs, O.; Cassell, G.; Fishman, N.; Guidos, R.; Levy, S.; Powers, J.; Norrby, R.; Tillotson, G.; Davies, R.; Projan, S.; Dawson, M.; Monnet, D.; Keogh-Brown, M.; Hand, K.; Garner, S.; Findlay, D.; Morel, C.; Wise, R.; Bax, R.; Burke, F.; Chopra, I.; Czaplewski, L.; Finch, R.; Livermore, D.; Piddock, L. J. V.; White, T. Discovery research: the scientific challenge of finding new antibiotics. J. Antimicrob. Chemother., 2011, 66, 1941-1944.
42. Wispelwey, B.; Schafer, K. R. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Audio, Transactions of the IRE Professional Group on 2010, 8, 1259-1271.
43. Ho, P. L. Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. J. Antimicrob. Chemother., 2002, 49, 1042-1044.
44. Silverman, G. A.; Luke, C. J.; Bhatia, S. R.; Long, O. S.; Vetica, A. C.; Perlmutter, D. H.; Pak, S. C. Modeling molecular and cellular aspects of human disease using the Nematode Caenorhabditis elegans. Pediatr. Res., 2009, 65, 10-18.
45. Kirienko, N. V.; Mani, K.; Fay, D. S. Cancer models in Caenorhabditis elegans. Dev. Dyn., 2010, 239, 1413-1448.
46. Moreau, D.; Kumar, P.; Wang, S. C.; Chaumet, A.; Chew, S. Y.; Chevalley, H.; Bard, F. Genome-wide RNAi screens identify genes required for ricin and PE intoxications. Dev. Cell, 2011, 21, 231-244.